Nancy Ryan Gray - Jun 6, 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Nancy Ryan Gray
Stock symbol
LGND
Transactions as of
Jun 6, 2025
Transactions value $
$0
Form type
4
Date filed
6/10/2025, 07:39 PM
Previous filing
Jun 18, 2024

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gray Nancy Ryan Director 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Nancy Ryan Gray 2025-06-10 0001714949

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +1.21K +17.56% $0.00 8.09K Jun 6, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 +5.78K $0.00 5.78K Jun 6, 2025 Common Stock 5.78K $105.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2 Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.